上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (1): 108-.doi: 10.3969/j.issn.1674-8115.2011.01.025

• 综述 • 上一篇    下一篇

肾素-血管紧张素系统阻滞剂治疗慢性肾脏病的研究进展

刘晓莉, 金惠敏   

  1. 上海交通大学 医学院附属第三人民医院肾内科, 上海 201900
  • 出版日期:2011-01-28 发布日期:2011-02-01
  • 通讯作者: 金惠敏, 电子信箱: hmjgli@yahoo.com.cn。
  • 作者简介:刘晓莉（1986—）, 女, 硕士生；电子信箱: liuxiaoli1986610@163.com。

Research progress of renin-angiotensin system blockade in treatment of chronic kidney disease

LIU Xiao-li, JIN Hui-min   

  1. Department of Nephrology, The Third People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201900, China
  • Online:2011-01-28 Published:2011-02-01

PDF (PC)

1642

摘要：

慢性肾脏病（CKD）的患病率呈逐年上升趋势，已成为威胁全世界公共健康的主要疾病之一。脂肪组织是导致CKD代谢紊乱的重要细胞因子来源，脂肪细胞因子能促进炎症并引起尿毒症相关的胰岛素抵抗，在CKD的发生和发展中起重要作用。肾素-血管紧张素系统（RAS）阻滞剂是治疗CKD的经典药物，通过调节脂肪细胞功能失调而延缓CKD的发展。文章就该方面的研究进展进行综述。

关键词: 慢性肾脏疾病, 肾素-血管紧张素系统, 阻滞剂, 脂肪细胞因子

Abstract:

With the increase of prevalence year by year, chronic kidney disease (CKD) has become one of the major diseases that threaten the public health all over the world. Adipose tissues are important resources of cytokines which cause metabolic disorder in CKD. These cytokines can promote inflammation, and lead to uremia-related insulin resistance, which may play an important role in the occurrence and development of CKD. Renin-angiotensin system blockade, which slows down the development of CKD by regulation of adipocyte dysfunction, is the classical drug in the treatment of CKD. The research progress of renin-angiotensin system blockade in the treatment of CKD is reviewed in this paper.

Key words: chronic kidney disease, rennin-angiotensin system, blockade, adipocytokines